Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESMERALD
2024-519317-66-00Phase 2Authorised
- Sponsor
- Aurealis Therapeutics
- Start
- May 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AUP-16 in diabetic foot ulcer (DFU), diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM), sponsored by Aurealis Therapeutics. Planned start May 2025; status: authorised.
02
Drugs
AUP-16
03
Conditions
diabetic foot ulcer (DFU)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-519317-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519317-66-00.